— Biotechnology company Amicus Therapeutics (NASDAQ: FOLD) reported a net loss of $356.4 million or $1.48 per share for fiscal 2019, compared to a loss of $349 million or $1.88 per share in the preceding year.
— Total revenues nearly doubled to $182.2 billion in 2019 from $91.25 million in 2018
— Adjusted operating expenses were $464.3 million in 2019, up 14% compared to fiscal 2018
— Expects revenues of Galafold, a therapy for Fabry disease in adults, to be in the range of $250 million to $260 million in fiscal 2020
— Estimates full-year operating expense to be in the range of $410 million to $420 million, which represents an increase from last year
— On track to continue ongoing operations well into 2022, making use of the current cash position
— Looks to complete Pompe Phase-3 PROPEL study, enroll pediatric studies and advance manufacturing to support 2021 BLA and MAA
Most Popular
IPO News: Monte Rosa Therapeutics will go public this week, here are a few things to know
Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated
IPO News: What to look for when Elevation Oncology makes its Wall Street debut
The healthcare sector is going through a phase of consolidation, creating fresh opportunities for emerging companies in a market that is slowly recovering from the pandemic. Several pharmaceuticals firms have
American Airlines (AAL): Here’s what may or may not work for this airline stock
Shares of American Airlines Group (NASDAQ: AAL) have gained 42% since the beginning of this year and 50% over the past 12 months. Despite this, there is a mixed sentiment
